Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Bibliographic Details
Main Authors:	Le, T, Farrar, J, Shikuma, C
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
by: Sandberg Johan K, et al.
Published: (2011-06-01)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
by: Jana L. Jacobs, et al.
Published: (2019-10-01)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection
by: Hamlyn, E, et al.
Published: (2012)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
by: Elizabeth Hamlyn, et al.
Published: (2012-01-01)

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
by: Alison L Hill, et al.
Published: (2016-04-01)

Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
by: A.L. Hill, et al.
Published: (2015-12-01)

HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
by: Daniela Souza Araújo de Angelis, et al.
Published: (2011-01-01)

Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy
by: Yuyang Tang, et al.
Published: (2023-06-01)

Low-level viremia episodes appear to affect the provirus composition of the circulating cellular HIV reservoir during antiretroviral therapy
by: Xiao Sun, et al.
Published: (2024-05-01)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
by: PLOS Pathogens Staff
Published: (2016-07-01)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
by: Leonardo Weissmann, et al.
Published: (2019-11-01)

Factors associated with viremia in people living with HIV on antiretroviral therapy in Guatemala
by: Dean W. Ortíz, et al.
Published: (2021-10-01)

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
by: Natalie F. McMyn, et al.
Published: (2023-09-01)

PP 7.10 – 00088 Macrophage-Tropic HIV-1 Variants Contribute to Pediatric Rebound Viremia off ART
by: K. Ganta, et al.
Published: (2022-12-01)

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.
by: Panagiotis Vagenas, et al.
Published: (2010-09-01)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
by: Llibre JM, et al.
Published: (2013-05-01)

In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia
by: Basiel Cole, et al.
Published: (2021-06-01)

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.
by: Alexander O Pasternak, et al.
Published: (2009-12-01)

Persistent Thalamic Sound Processing Despite Profound Cochlear Denervation
by: Anna R. Chambers, et al.
Published: (2016-08-01)

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
by: Alessandra Borgognone, et al.
Published: (2022-04-01)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
by: Azwidowi Lukhwareni, et al.
Published: (2020-06-01)

PP 1.37 – 00186 Investigating Short-Term Effects of COVID-19 mRNA Vaccination on Plasma Viremia and Intact HIV Reservoir Size in Individuals Receiving Antiretroviral Therapy (ART)
by: M.C. Duncan, et al.
Published: (2022-12-01)

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
by: Veronica Obregon-Perko, et al.
Published: (2021-12-01)

Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings
by: Ashwini Shete, et al.
Published: (2020-07-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy.
by: Nicole E Behrens, et al.
Published: (2020-01-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy
by: Nicole E. Behrens, et al.
Published: (2020-01-01)

Plasma inflammatory biomarkers predict CD4+ T-cell recovery and viral rebound in HIV-1 infected Africans on suppressive antiretroviral therapy
by: Kroeze, S, et al.
Published: (2020)

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
by: Constance Delaugerre, et al.
Published: (2012-01-01)

Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
by: Zied Gaifer MBBS, MD, et al.
Published: (2020-12-01)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
by: You Park, et al.
Published: (2017-11-01)

Rate of HIV rebound and CD4 T cell kinetics in an ageing population on successful antiretroviral therapy
by: Abhishek Katiyar, et al.
Published: (2018-05-01)

Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.
by: Adrian Schmid, et al.
Published: (2010-10-01)

HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites
by: Nitin K Saksena, et al.
Published: (2010-06-01)

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.
by: Anthony R Cillo, et al.
Published: (2014-01-01)

Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy
by: Mehwish Younas, et al.
Published: (2021-03-01)

Benefits and limitations of different study designs for long‐acting antiretroviral therapy among people living with HIV with viremia
by: Monica Gandhi, et al.
Published: (2023-07-01)

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
by: Maud Mavigner, et al.
Published: (2009-10-01)

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
by: Olof Elvstam, et al.
Published: (2017-01-01)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
by: María Rosa López-Huertas, et al.
Published: (2020-12-01)